Barcelona, Spain (PRWEB) December 3, 2004
The nomination of FranÃ§ois Arcand as Director General (CEO) of ERA Plantech S.L., effective immediately, was announced during BioSpain by Dr. Luis Ruiz-Avila, on behalf of the board of directors. ÂThis experienced CEO will lead ERA where it belongs in the international league of biopharmaceutical productionÂ, said Dr. Ruiz-Avila.
ERA uses ZeraÂ, a suite of proprietary biotechnologies, to improve the manufacturing productivity of plant-made pharmaceuticals and other protein-based products of high value. ZeraÂ assemble Protein Bodies in plant cells to accumulate recombinant products, and eases their recovery.
ÂWith ZeraÂ, drug manufacturing in plants should be easier and more affordable,Â believes FranÃ§ois Arcand. ÂThe simplicity and elegance of Dra. LudevidÂs discovery has a seducing quality.Â ZeraÂ will be presented at the Conference on Plant-made Pharmaceuticals in MontrÃ©al (Jan 30 to Feb. 2, 2005).
Mr. Arcand obtained a MBA from the Executive Program of John Molson School of Business (Concordia University, MontrÃ©al). He is the co-founder of Medicago inc., a plant-factory company from QuÃ©bec City (Canada), and the president of the Society for Moleculture, a non-for-profit organization that supports the emergence of plant-factories (http://www.cpmp2005.org).
ZeraÂ was discovered by the team of Dra. Dolors Ludevid-MÃºgica from the Spanish Consejo Superior de Investigaciones CientÃficas (CSIC), and is developed by ERA, a private company whose state of the art facilities are located in the Parc Cientific de Barcelona (http://www.eraplantech.com).
For press inquiries:
+ (34) 93 49 34 773
# # #